Exploratory Tympanotomy Laboratory Medicine

1. Sourdille M. New Technique in the Surgical Treatment of Severe and Progressive Deafness from Otosclerosis. Bull N Y Acad Med. 1937 Dec. 13(12):673-91. [QxMD MEDLINE Link].

2. Lempert J. Improvement of hearing in cases of otosclerosis. Arch Otolaryngol. 1938. 28:42-97.

3. Rosen S. Palpation of stapes for fixation; preliminary procedure to determine fenestration suitability in otosclerosis. AMA Arch Otolaryngol. 1952 Dec. 56(6):610-5. [QxMD MEDLINE Link].

4. Prenzler NK, Schwab B, Kaplan DM, El-Saied S. The role of explorative tympanotomy in patients with sudden sensorineural hearing loss with and without perilymphatic fistula. Am J Otolaryngol. 2018 Jan - Feb. 39 (1):46-49. [QxMD MEDLINE Link].

5. Paparella MM, Koutroupas S. Exploratory tympanotomy revisited. Laryngoscope. 1982 May. 92(5):531-4. [QxMD MEDLINE Link].

6. Robertson G, Mills R. Findings at exploratory tympanotomy for conductive hearing loss. J Laryngol Otol. 2009 Oct. 123(10):1087-9. [QxMD MEDLINE Link].

7. Basson OJ, van Lierop AC. Conductive hearing loss after head trauma: review of ossicular pathology, management and outcomes. J Laryngol Otol. 2009 Feb. 123(2):177-81. [QxMD MEDLINE Link].

Matthew Ng, MD Associate Professor, Department of Otolaryngology-Head and Neck Surgery, University of Nevada, Las Vegas, School of Medicine

Matthew Ng, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Association for the Advancement of Science, American College of Surgeons, North American Skull Base Society, Society of University Otolaryngologists-Head and Neck Surgeons

Disclosure: Nothing to disclose.

Arlen D Meyers, MD, MBA Professor of Otolaryngology, Dentistry, and Engineering, University of Colorado School of Medicine

Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cerescan; Ryte; Neosoma; MI10<br/>Received income in an amount equal to or greater than $250 from: Neosoma; Cyberionix (CYBX)<br/>Received ownership interest from Cerescan for consulting for: Neosoma, MI10.

• Print this section
• Print the entire contents of
• Print the entire contents of article